Leal T, et al. Identifying resistance to immune checkpoint inhibitors by screening for PD-L1 and MHC I expression on CTCS in pts with NSCLC. IASLC 2018; abstract P3.04-08.
Adjuvant dabrafenib plus trametinib bij stadium III-melanoom: 10 jaar follow-up
aug 2024 | Dermato-oncologie